Millennium Management LLC Has $1.75 Million Position in Zura Bio Limited (NASDAQ:ZURA)

Millennium Management LLC lifted its position in shares of Zura Bio Limited (NASDAQ:ZURA) by 1,499.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 701,278 shares of the company’s stock after purchasing an additional 657,420 shares during the period. Millennium Management LLC owned 1.07% of Zura Bio worth $1,753,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the company. American Century Companies Inc. bought a new position in Zura Bio during the fourth quarter worth about $27,000. Prudential Financial Inc. acquired a new stake in shares of Zura Bio in the fourth quarter valued at approximately $28,000. XTX Topco Ltd bought a new position in shares of Zura Bio during the 4th quarter worth approximately $44,000. SG Americas Securities LLC increased its holdings in shares of Zura Bio by 51.6% during the 4th quarter. SG Americas Securities LLC now owns 23,005 shares of the company’s stock worth $58,000 after acquiring an additional 7,828 shares during the last quarter. Finally, Wells Fargo & Company MN increased its holdings in shares of Zura Bio by 68.6% during the 4th quarter. Wells Fargo & Company MN now owns 23,053 shares of the company’s stock worth $58,000 after acquiring an additional 9,379 shares during the last quarter. 61.14% of the stock is currently owned by institutional investors and hedge funds.

Zura Bio Stock Performance

ZURA stock opened at $1.01 on Tuesday. Zura Bio Limited has a 52 week low of $0.97 and a 52 week high of $5.50. The company has a market capitalization of $69.06 million, a PE ratio of -1.44 and a beta of 0.05. The company’s 50-day simple moving average is $1.21 and its 200 day simple moving average is $1.71.

Zura Bio (NASDAQ:ZURA) last announced its earnings results on Thursday, May 8th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.02). On average, analysts forecast that Zura Bio Limited will post -0.65 EPS for the current year.

Wall Street Analyst Weigh In

ZURA has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating on shares of Zura Bio in a research report on Thursday, April 3rd. Oppenheimer reduced their target price on shares of Zura Bio from $19.00 to $17.00 and set an “outperform” rating for the company in a report on Friday, May 9th. Guggenheim reiterated a “buy” rating and issued a $15.00 price target on shares of Zura Bio in a research note on Wednesday, March 26th. Finally, Chardan Capital cut their price objective on shares of Zura Bio from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, March 26th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $14.33.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.